AOGRAdvances in Obstetrics and Gynecology Research3083-48722981-8060Bio-Byword Scientific Publishing Pty. Ltd.10.26689/aogr.v3i1.9827ArticleClinical Analysis of Placental Growth Factor and Soluble FMS-Like Tyrosine Kinase-1 in Serum on the Severity of Preeclampsiahttps://artdesignp.com/journal/AOGR/3/1/10.26689/aogr.v3i1.9827XuYuan,YuanGefen2025312025-03-10Objective: This study aims to analyze the differences in the expression of Placental Growth Factor (PLGF) and soluble Fms-like tyrosine kinase-1 (sFlt-1) in serum and their clinical significance in the severity of preeclampsia. Methods: This study selected 58 preeclampsia patients who underwent prenatal check-ups and gave birth in our hospital from September 2021 to September 2023 as the observation group. Based on the severity of their condition, they were divided into a mild group (n = 38) and a severe group (n = 20). Additionally, 795 healthy pregnant women who underwent prenatal check-ups in the hospital during the same period were included as the control group. Pearson correlation analysis was used to examine the correlation between serum sFlt-1 and PLGF expression and the severity of preeclampsia. Results: The observation group had higher sFlt-1 and lower PLGF levels compared to the control group. The severe group had higher sFlt-1 levels and lower PLGF levels compared to the mild group. The 24-hour urinary protein level was significantly higher in the observation group than in the control group (p < 0.05). Pearson correlation analysis revealed a positive correlation between 24-hour urinary protein quantification and serum sFlt-1 levels and a negative correlation with PLGF expression in preeclampsia patients (p < 0.05). Conclusion: The expression of sFlt-1 and PLGF in serum is closely related to the severity of preeclampsia, suggesting their potential as biomarkers for assessing the severity of preeclampsia.

Song Z, Li Y, Li J, et al., 2024, Relationship Between Dietary Vitamin B3 Intake During Pregnancy and the Risk of Preeclampsia and Its Clinical Subtypes. Nursing Research, 38(7): 1146–1153.

Ives CW, Sinkey R, Rajapreyar I, et al., 2020, Preeclampsia Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. Journal of American College of Cardiology, 76(14): 1690–1702.

Xu X, Xu B, 2022, Expression of Serum Soluble Fms-Like Tyrosine Kinase-1, Vascular Endothelial Growth Factor, and Placental Growth Factor in High-Risk Preeclampsia Women and Their Correlation With Disease Severity. Chinese Journal of Maternal and Child Health Care, 37(5): 895–897.

Guo X, Tang X, Ning S, 2024, Correlation Between Serum Soluble Vascular Endothelial Growth Factor Receptor-1/Placental Growth Factor Ratio, Uterine Artery Pulsatility Index, and Preeclampsia in the Second Trimester. China Medical Herald, 21(15): 78–80.

Xu X, Guo L, Xu L, et al., 2019, Clinical Significance of Detecting Serum PLGF, sFlt-1, Ca2+, 25-(OH)-D Levels and Analyzing Other Risk Factors in Predicting Preeclampsia. Journal of Modern Laboratory Medicine, 34(5): 35–39.

Xie X, Kong B, Duan T, 2018, Obstetrics and Gynecology. 9th ed. People’s Medical Publishing House, Beijing, 83–91.

Yang L, Xiao J, Shi H, et al., 2024, Application Value of Placental Growth Factor, Soluble Fms-Like Tyrosine Kinase-1, and Glycated Fibronectin in the Prediction of Preeclampsia. Journal of Chongqing Medical University, 49(1): 50–54.

Huang Y, Meng L, Lu H, et al., 2023, Predictive Efficacy of Serum PIGF, sFlt-1, and PLGF Levels for Hypertensive Disorders of Pregnancy and Their Relationship With the Incidence of Preeclampsia. Guangdong Medical Journal, 44(3): 284–287.

Song F, Ma L, He X, 2024, Application of sFlt-1, PLGF, and PAPP-A in the Clinical Diagnosis and Prognosis of Preeclampsia. Molecular Diagnostics & Therapy, 16(2): 243–246.

Zhu Y, Xiao Y, Fu J, et al., 2022, Serum Levels and Significance of STOX1 and Soluble Fms-Like Tyrosine Kinase-1 in Preeclampsia Pregnant Women. Hebei Medical Journal, 28(1): 57–61.

Zhao S, Liu X, Wang J, et al., 2020, Correlation Between Soluble Fms-Like Tyrosine Kinase-1 and Placental Growth Factor in Serum and the Severity of Preeclampsia. Medical Review2020, 26(24): 4988–4992.